摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-bromo-3-(1-methylethoxy)-2-propenal

中文名称
——
中文别名
——
英文名称
2-bromo-3-(1-methylethoxy)-2-propenal
英文别名
(E)-2-bromo-3-isopropoxyacrylaldehyde;(E)-2-bromo-3-propan-2-yloxyprop-2-enal
2-bromo-3-(1-methylethoxy)-2-propenal化学式
CAS
——
化学式
C6H9BrO2
mdl
——
分子量
193.04
InChiKey
UCDIXJKWUCLMJK-GQCTYLIASA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1.6
  • 重原子数:
    9
  • 可旋转键数:
    3
  • 环数:
    0.0
  • sp3杂化的碳原子比例:
    0.5
  • 拓扑面积:
    26.3
  • 氢给体数:
    0
  • 氢受体数:
    2

反应信息

  • 作为反应物:
    描述:
    N-苯基苄脒2-bromo-3-(1-methylethoxy)-2-propenalpotassium carbonate 作用下, 以 氯仿 为溶剂, 反应 18.0h, 以52%的产率得到2,3-Diphenylimidazole-4-carbaldehyde
    参考文献:
    名称:
    A New Regioselective Synthesis of 1,2,5-Trisubstituted 1H-Imidazoles and Its Application to the Development of Eprosartan
    摘要:
    A new method is presented for the preparation of 1,2-disubstitued-1H-imidazole-5-carboxaldehydes by the reaction of N-monosubstituted amidines with 2-halo-3-alkoxy-2-propenals. The reaction is highly regioselective with ratios of 1,2,5:1,2,4-imidazolecarboxaldehydes ranging from 85:15 to 100: 0. This methodology could be extended with similar results to the synthesis of imidazole-g-nitriles by the reaction of 2-bromo-3-methoxy-2-propenenitrile with N-monosubstituted amidines.
    DOI:
    10.1021/jo971304f
  • 作为产物:
    描述:
    2-溴丙二醛异丙醇对甲苯磺酸 作用下, 以 为溶剂, 反应 3.0h, 生成 2-bromo-3-(1-methylethoxy)-2-propenal
    参考文献:
    名称:
    基于唑的非拟肽血浆蛋白酶抑制剂
    摘要:
    抗药性疟原虫的传播促使人们寻找新的抗疟药。疟疾天冬氨酸蛋白酶——血浆蛋白酶 (Plms)——在疟原虫生命周期的多个阶段有差异表达,被认为是有吸引力的药物靶点。我们报告了新型唑类非肽模拟血浆蛋白酶抑制剂的开发,该抑制剂是通过对 Actelion 氨基哌嗪抑制剂中的酰胺部分进行生物等排取代而设计的。最好的基于三唑的抑制剂对 Plm II 表现出亚微摩尔的效力,这与母体 Actelion 化合物相当。新抑制剂可作为开发无耐药性抗疟药的起点,靶向非消化性 Plm IX 或 X,这对疟原虫生命周期至关重要。
    DOI:
    10.1002/ardp.201800151
点击查看最新优质反应信息

文献信息

  • Imidazole derivatives as PDE10A enzyme inhibitors
    申请人:Kehler Jan
    公开号:US20120129836A1
    公开(公告)日:2012-05-24
    This invention is directed to compounds, which are PDE10A enzyme inhibitors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. The present invention also provides processes for the preparation of the compounds of formula I. The present invention further provides a method of treating a subject suffering from a neurodegenerative disorder comprising administering to the subject a therapeutically effective amount of a compound of formula I. The present invention also provides a method of treating a subject suffering from a drug addiction comprising administering to the subject a therapeutically effective amount of a compound of formula I. The present invention further provides a method of treating a subject suffering from a psychiatric disorder comprising administering to the subject a therapeutically effective amount of a compound of formula I.
    这项发明涉及一类PDE10A酶抑制剂化合物。该发明提供了一种包含该发明化合物的治疗有效量和药用载体的药物组合物。本发明还提供了制备式I化合物的方法。本发明还提供了一种治疗神经退行性疾病的方法,包括向患有神经退行性疾病的受试者施用式I化合物的治疗有效量。本发明还提供了一种治疗药物成瘾的方法,包括向患有药物成瘾的受试者施用式I化合物的治疗有效量。本发明还提供了一种治疗精神障碍的方法,包括向患有精神障碍的受试者施用式I化合物的治疗有效量。
  • Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
    申请人:Edwards Louise
    公开号:US20050272779A1
    公开(公告)日:2005-12-08
    The present invention relates to new compounds of formula I, to pharmaceutical formulations containing the compounds, and to the use of the compounds in the prevention and/or treatment of mGluR5 receptor-mediated disorders.
    本发明涉及公式I的新化合物,包含该化合物的药物配方,以及利用该化合物预防和/或治疗mGluR5受体介导的疾病的用途。
  • [EN] SUBSTITUTED AMINOALKYLAZOLES AS MALARIAL ASPARTIC PROTEASE INHIBITORS<br/>[FR] AMINOALKYLAZOLES SUBSTITUÉS UTILISÉS COMME INHIBITEURS DE LA PROTÉASE ASPARTIQUE DU PALUDISME
    申请人:LATVIAN INST ORGANIC SYNTHESIS
    公开号:WO2017069601A1
    公开(公告)日:2017-04-27
    The present invention relates to novel aminoalkylazoles acting as inhibitors of malarial protease plasmepsin II. These can be used as medicines or as constituent of medicines for the treatment of malaria infection.
    本发明涉及作为疟疾蛋白酶质体酶II抑制剂的新型氨基烷基唑类化合物。这些化合物可用作治疗疟疾感染的药物或药物成分。
  • Processes For Preparing Bicyclic Oxazine Carboxaldehyde and Beta-Lactamase Inhibitors
    申请人:Kremer Kenneth Alfred Martin
    公开号:US20090018332A1
    公开(公告)日:2009-01-15
    The invention relates to processes for the preparation of the bicyclic oxazine carboxaldehyde Compound 1: The invention also relates to the use of Compound 1 in the preparation of □-lactamase inhibitors.
    本发明涉及制备双环氧噁啉羰基醛化合物1的工艺。本发明还涉及将化合物1用于制备□-内酰胺酶抑制剂的用途。
  • Bicyclic and Tricyclic Substituted 6-Methylidene Carbapenems as Broad Spectrum Beta-Lactamase Inhibitors
    申请人:Mansour Tarek Suhayl
    公开号:US20100063023A1
    公开(公告)日:2010-03-11
    Provided is a β-lactamase antibiotic and a compound of formula I, a process of producing the compound, pharmaceutical compositions and the use thereof for the treatment of bacterial infection or disease in a patient in need thereof.
    本文提供了一种β-内酰胺酶抗生素和一种I式化合物,以及制备该化合物的过程、制药组合物及其用于治疗患有细菌感染或疾病的患者。
查看更多